Brendan G. Carr, MD, MA, MS, is the Chief Executive Officer of the Mount Sinai Health System. Mount Sinai, based in New York City, is one of the nation’s most recognized free-standing academic health systems. Mount Sinai is home to the Icahn School of Medicine at Mount Sinai, the Mount Sinai Phillips School of Nursing, the Graduate School of Biomedical Sciences, seven hospitals, and more than 400 ambulatory practices.

Dr. Carr is a nationally recognized leader in academic medicine and health policy. He leads as a physician-scientist. He completed his residency in emergency medicine, as well as fellowships in trauma and surgical critical care and in health policy research. In addition to clinical practice, he maintained a decades-long funded research portfolio and served in multiple policy roles within the U.S. Department of Health and Human Services. His career has focused on transforming the health care delivery system in order to improve patient outcomes. Dr. Carr is an elected member of the National Academy of Medicine, and an advisor to domestic and international health care organizations.

Kenneth L. Davis, MD, is the Executive Vice Chairman, Boards of Trustees of the Mount Sinai Health System in New York City, one of the nation’s largest integrated health systems, which includes the Icahn School of Medicine at Mount Sinai, eight hospitals, and more than 400 ambulatory sites. He is a leader in the move away from fee-for-service medicine to population health with the aim of keeping more patients healthy and out of the hospital. As a neurobiologist, Dr. Davis conducted pioneering research that led the FDA to approve four of the first five drugs for treating Alzheimer’s disease. In 2002, he was elected to the Institute of Medicine of the National Academy of Sciences. Dr. Davis is one of the most highly cited researchers in the field of brain diseases. His awards include the George H. W. Bush Lifetime of Leadership Award from Yale. In 2014 he was named a trustee of the Aspen Institute.

Sandra M. Brunson, MD, is the Co-Founder and Chief Financial Officer of the Second Round Foundation, Inc., where she provides strategic financial leadership and plays an integral role in advancing the Foundation’s mission to create sustainable, community-centered impact. Known for her thoughtful stewardship, collaborative leadership style, and commitment to service, Dr. Brunson ensures the organization’s programs and partnerships are aligned, accountable, and positioned for long-term success.

Through her leadership, the Second Round Foundation has cultivated meaningful partnerships with organizations such as The Stevenson Foundation and DREAM Charter School—collaborations that reflect the Foundation’s commitment to creating access and opportunity for young people through education, sport, and community investment.

With more than 30 years of experience spanning litigation support, project management, and strategic partnerships, she has built a highly respected career at the intersection of the legal and business sectors.

She earned her bachelor’s degree in business law from Temple University.

Fanny Elahi, MD, PhD, is an Associate Professor of Neurology; Neuroscience; Artificial Intelligence and Human Health; and Pathology, Molecular and Cell Based Medicine at the Icahn School of Medicine at Mount Sinai. A physician-scientist, Dr. Elahi serves as Director of The Glickenhaus Center for Successful Aging and co-leads the Biomarkers and Genetics Research of the Mount Sinai Alzheimer’s Disease Research Center, where she oversees the development of novel blood-based biomarkers for neurodegenerative diseases. She also directs the Davos Alzheimer’s Collaborative Healthcare System Preparedness and Accurate Diagnosis program at Mount Sinai and oversees multiple NIH-supported projects. Widely recognized for pioneering work at the intersection of vascular biology and neurodegeneration, her research employs data-driven approaches to discover and test mechanisms underlying vascular contributions to cognitive impairment and dementia, with the goal of therapeutically targeting the vasculature to stave off dementia. Her lab integrates molecular and cellular phenotyping across diverse human biospecimens with iPSC-derived in vitro models to identify therapeutic targets for vascular contributions to dementia. Dr. Elahi has received numerous honors for her contributions to dementia research, including the prestigious New Vision Award, which recognizes innovative research in Alzheimer’s disease and related dementias, and has authored seminal publications in leading scientific journals.

Dr. Fayad is Principal Investigator on multiple major grants, including five NIH-funded projects (3 R01s, 2 P01s), with support from the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Disease, and the National Institute on Drug Abuse. A leader in biomedical engineering, his interdisciplinary research integrates artificial intelligence (AI), imaging, and nanomedicine to advance precision medicine, particularly in cardiovascular disease.

He has been a Clarivate Highly Cited Researcher since 2018, with more than 174,000 citations and an h-index of 137. Notable contributions include MRI vessel-wall imaging (leading to CARADS), FDG PET imaging of vascular inflammation, and uncovering links between amygdala activity, inflammation, and cardiovascular risk. His research on nanoparticles based on HDL (“good” cholesterol) to modulate immunity is advancing toward clinical use in cancer, autoimmune diseases, and transplant rejection.

Current projects span cardiovascular, neuroimmune, and transplant-focused research, including stress-induced immune dysregulation; MVP and arrhythmia risk; CUD-related carotid atherosclerosis and cognition; cardiac sarcoidosis therapy monitoring; and immune tracking in organ rejection using nanobiologics.

Dr. Fayad also leads the Mount Sinai DigiTwin Project, an AI-driven initiative to personalize health optimization by integrating real-time data, imaging, and analytics—starting with cardiovascular health and expanding to broader wellness applications.

Sidney Hankerson, MD, MBA, is Vice Chair, Community Engagement, Department of Psychiatry, and Director of Mental Health Equity Research, Institute for Health Equity Research Center, Icahn School of Medicine at Mount Sinai. His research increases access to mental health care and creates cultures of wellness by partnering with Fortune 500 corporations, sports leagues, and trusted community-based organizations.

He is a member of the National Football League’s Behavioral Health Committee and is a consulting psychiatrist for the National Basketball Association. He received the President’s Lifetime Achievement Service Award, under President Joseph L. Biden, Jr. and the American Psychiatric Association’s Distinguished Service Award for his contributions to psychiatry in the United States. He has presented at Fortune 500 corporations, as well as the White House, United Nations, National Institute of Mental Health, and U.S. Department of Health and Human Services, and was featured in the PBS documentary Mysteries of Mental Illness. The National Academy of Medicine named him in its Emerging Leaders in Health and Medicine program in 2021.

Dr. Hankerson completed a dual MD/MBA program from Emory University, where he was medical school class president, and also completed his psychiatry residency there. He completed a research fellowship at Columbia University Irving Medical Center.

Eimear E. Kenny, PhD, is an internationally recognized leader in genomics, artificial intelligence, and precision medicine whose work is helping to redefine how health systems predict, prevent, and personalize care across the lifespan. She is the Mount Sinai Professor and Chair of Genomic Health at the Icahn School of Medicine at Mount Sinai and Founding Director of the Institute for Genomic Health, where she leads efforts to integrate genomics, large-scale health data, and digital tools into routine clinical care. Dr. Kenny’s research focuses on moving medicine upstream—from reactive treatment to earlier prediction and prevention—by combining genomic information with clinical records, family history, biomarkers, and real-world health data to better understand individual risk and resilience. She is helping build one of the first large-scale health system efforts to integrate genomic screening into routine care and has led studies returning personalized genomic risk information to tens of thousands of patients to understand how predictive health can be responsibly implemented in everyday medicine. A leading voice in the future of precision health, Dr. Kenny has published more than 200 scientific papers in leading journals and advises multiple national and international initiatives focused on the future of genomic and preventive health.

Anuradha (Anu) Lala-Trindade (Lala), MD, is a Professor of Medicine (Cardiology); Population Health Science and Policy; and Obstetrics, Gynecology and Reproductive Sciences at the Icahn School of Medicine at Mount Sinai. An internationally recognized cardiologist, Dr. Lala’s clinical expertise spans the full spectrum of heart function care—from prevention to advanced therapies. She is committed to whole-person, integrative care and has particular expertise in the diagnosis and management of cardiometabolic health in women during midlife.

Beyond her clinical practice, Dr. Lala is deeply engaged in advancing the field. She is Program Director of the Advanced Heart Failure and Transplant Fellowship at Mount Sinai; Co-Editor-in-Chief of the Journal of Cardiac Failure; and is an active contributor to the national committees of the American Heart Association, American College of Cardiology, and the Heart Failure Society of America.

Dr. Lala was named an American Heart Association Young Professionals Society Honoree for her commitment to education and cardiovascular health awareness and received the Proctor H. Harvey Teaching Award from the American College of Cardiology, honoring her dedication and excellence in medical education.

A Super Bowl champion and one of his generation’s most influential athletes, Russell Wilson continues to inspire through his unwavering commitment to excellence, not only on the field but also through his community work and entrepreneurship.

Wilson completed his 14th NFL season as one of the first black quarterbacks to play for the New York Giants. Wilson, a 10-time Pro Bowler, currently ranks fifth all-time in career passer rating, and has 123 career wins, exemplifying his dominance and establishing his place as one of the league’s premier players and champions.

Off the field, Wilson’s commitment to cause work led him to create the Why Not You Foundation, a nonprofit organization dedicated to fostering real and lasting change in the world by motivating and empowering today’s youth. Russell spends every Tuesday at Mount Sinai Hospital, connecting with pediatric patients and their families to offer support, encouragement, and joy. In recognition of his philanthropic impact, Wilson earned the 2020 NFL Walter Payton Man of the Year Award and the 2022 Bart Starr Award

Sarah Wood, MD, MS, is Division Chief of Adolescent Medicine, Icahn School of Medicine at Mount Sinai, and Director of the Mount Sinai Adolescent Health Center, Mount Sinai Health System. A physician-scientist with a career mission to improve effective and equitable health care for youth, she has received funding from the National Institutes of Health and Gilead Sciences for her research, which blends data science, human systems engineering, behavioral intervention development, and implementation science to generate, test, and translate innovative strategies to improve the mental and sexual health of adolescents and young adults. She is a passionate mentor and advocate for learners who are traditionally underrepresented in medicine.

Dr. Wood obtained her undergraduate degree from DePaul University and her medical degree from Drexel University, where she was awarded a Doris Duke International Clinical Research Fellowship. She completed her pediatrics residency and adolescent medicine fellowship at the Children’s Hospital of Philadelphia, earning a Master of Science in Health Policy Research from the University of Pennsylvania. She served on the faculty at the University of Pennsylvania and the Children’s Hospital of Philadelphia as Co-Director of the Clinical Core of the Penn Center for AIDS Research until 2024, when she transitioned to Mount Sinai.

Rachel Yehuda, PhD, is the Chemers Neustein Family Professor of Trauma and Resilience at Icahn School of Medicine at Mount Sinai. She founded Mount Sinai’s Traumatic Stress Studies Division in 1991 and, in 2020, she established The Parsons Research Center for Psychedelic Healing, which she currently directs. At the James J. Peters Veterans Affairs Medical Center in the Bronx, she directs the Center for Psychedelic Therapy and previously served as Director of Mental Health for 15 years.